SARS-CoV-2 immune evasion by variant B.1.427/B.1.429

Matthew McCallum, Jessica Bassi, Anna De Marco, Alex Chen, Alexandra C. Walls, Julia di Iulio, M. Alejandra Tortorici, Mary-Jane Navarro, Chiara Silacci-Fregni, Christian Saliba,

bioRxiv (Cold Spring Harbor Laboratory) · 2021 · 140 citations · 59 references

DOIFull text

Open access

Concepts

TL;DR

SARS‑CoV‑2 enters cells via its spike protein, and the emerging B.1.427/B.1.429 (CAL.20C) variant carries three spike mutations (S13I, W152C, L452R) whose effect on neutralizing antibody responses from infection or Wuhan‑1‑based vaccines is uncertain. The study aimed to evaluate whether neutralizing antibody responses from natural infection or mRNA vaccination are affected by the B.1.427/B.429 spike mutations. Neutralization assays were performed using pseudoviruses bearing either the wildtype or B.1.427/B.429 spike protein to test plasma from vaccinated or convalescent individuals. Neutralization of the B.1.427/B.429 variant was reduced 3–6 fold in plasma, the L452R mutation abrogated activity of many RBD‑specific mAbs, and a structural shift caused by S13I eliminated NTD‑targeted mAb neutralization, highlighting the role of signal‑peptide variants in immune evasion and viral evolution.

Abstract

SARS-CoV-2 entry is mediated by the spike (S) glycoprotein which contains the receptor-binding domain (RBD) and the N-terminal domain (NTD) as the two main targets of neutralizing antibodies (Abs). A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429) was originally detected in California and is currently spreading throughout the US and 29 additional countries. It is unclear whether antibody responses to SARS-CoV-2 infection or to the prototypic Wuhan-1 isolate-based vaccines will be impacted by the three B.1.427/B.1.429 S mutations: S13I, W152C and L452R. Here, we assessed neutralizing Ab responses following natural infection or mRNA vaccination using pseudoviruses expressing the wildtype or the B.1.427/B.1.429 S protein. Plasma from vaccinated or convalescent individuals exhibited neutralizing titers, which were reduced 3-6 fold against the B.1.427/B.1.429 variant relative to wildtype pseudoviruses. The RBD L452R mutation reduced or abolished neutralizing activity of 14 out of 35 RBD-specific monoclonal antibodies (mAbs), including three clinical-stage mAbs. Furthermore, we observed a complete loss of B.1.427/B.1.429 neutralization for a panel of mAbs targeting the N-terminal domain due to a large structural rearrangement of the NTD antigenic supersite involving an S13I-mediated shift of the signal peptide cleavage site. These data warrant closer monitoring of signal peptide variants and their involvement in immune evasion and show that Abs directed to the NTD impose a selection pressure driving SARS-CoV-2 viral evolution through conventional and unconventional escape mechanisms.

References

59